The use of humoral responses as a marker of CMV burden in HIV patients on ART requires consideration of T-cell recovery and persistent B-cell activation.
Samantha J BruntSilvia LeeLloyd D'OrsognaChristine BundellSally A BurrowsPatricia PricePublished in: Disease markers (2014)
CMV antibody titres peak on ART and remain high. A correlation between CMV antibody and sBAFF suggests a role for HIV-induced B-cell pathology that may affect its use as a marker of CMV burden.
Keyphrases
- antiretroviral therapy
- hiv infected
- hiv positive
- human immunodeficiency virus
- end stage renal disease
- hiv testing
- hiv aids
- hepatitis c virus
- ejection fraction
- newly diagnosed
- immune response
- chronic kidney disease
- men who have sex with men
- prognostic factors
- peritoneal dialysis
- risk factors
- south africa
- high glucose
- drug induced
- oxidative stress
- patient reported